Dr Richard Hubner, Consultant Medical Oncologist
Dr Richard Hubner
Consultant Medical Oncologist
Dr Richard Hubner MA BM BCh MRCP PhD
Consultant Medical Oncologist
Dr Richard Hubner
Consultant Medical Oncologist MA BM BCh MRCP PhD
About Dr Richard Hubner
GMC number: 4530419
Year qualified: 1998
Place of primary qualification: Oxford University
Areas of expertise
- Upper gastrointestinal
- Hepatopancreatobiliary cancer
- Cancer oesophagus
- Stomach
- Pancreas
- Bile duct
- Gallbladder
- Liver
- Neuroendocrine system
Professional memberships
Articles by Dr Richard Hubner
add-aspirin trial: a phase iii, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors
Phase ii study of the antibody-drug conjugate tak-264 (mln0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase c
A phase ii study of antibody-drug conjugate, tak-264 (mln0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase c
Targeting the epidermal growth factor receptor in addition to chemotherapy in patients with advanced pancreatic cancer: a systematic review and meta-analysis
Abstract 3960: combined circulating tumour cell (ctc) and circulating tumor dna (ctdna) analysis of blood from patients with pancreatic cancer
Adi-peg 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma